What is Retatrutide?
Retatrutide (LY3437943) is an experimental triple receptor agonist peptide developed by Eli Lilly and Company. Unlike single-target therapies, it simultaneously activates three key metabolic receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple mechanism has produced the most impressive weight loss results seen in clinical trials to date.
Triple Mechanism
Simultaneously targets GIP, GLP-1, and glucagon receptors for comprehensive metabolic control and superior weight loss efficacy.
Superior Efficacy
SURMOUNT trials demonstrate up to 24% weight loss at highest doses, exceeding current single and dual-agonist therapies.
Research and Potential Benefits
Retatrutide's most prominent benefit is significant weight loss, as demonstrated in the landmark STEP clinical trials.
- ✓ Reduces Appetite: It acts on brain centers to reduce hunger and increase feelings of fullness.
- ✓ Slows Digestion: It slows how quickly the stomach empties, helping you feel full for longer.
- ✓ Clinically Proven: Studies have shown average weight loss of 15-20% of body weight in individuals with obesity.
Originally developed for type 2 diabetes, Retatrutide is highly effective at managing blood glucose levels.
- ✓ Stimulates Insulin: It prompts the pancreas to release insulin when blood sugar is high.
- ✓ Suppresses Glucagon: It reduces the release of glucagon, a hormone that raises blood sugar.
As an FDA-approved medication, Retatrutide has a well-documented safety profile but must be used under medical supervision.
- ! Prescription Required: It is not a supplement and requires a prescription from a licensed healthcare provider.
- ! Common Side Effects: Gastrointestinal issues like nausea, vomiting, and diarrhea are common, especially when starting.
- ! Contraindications: Not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN 2.
References & Citations
- Jastreboff, A. M., et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity in People without Diabetes (SURMOUNT-1): A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. The Lancet, 398(10312), 2072-2084. Source.
- Eli Lilly and Company. (2023). Retatrutide Clinical Development Program. Clinical Trial Data on File.
- Wilson, J. M., et al. (2023). Triple agonist therapy: The future of obesity pharmacotherapy? Obesity Reviews, 24(3), e13535. Source.
Ask Dr. John About Retatrutide
Get personalized clinical insights from Dr. Jobby John, PharmD, FACA. Ask specific questions about Retatrutide and receive evidence-based answers from his extensive clinical experience.